#POLARGO
🎙️ Blackstar POLAR GO — Available Now at GN Music!
A compact mobile audio interface built for musicians and creators. Record vocals, instruments, podcasts & content wherever inspiration hits.
🚚 Free U.S. Shipping
🛒 gnmusic.us
#Blackstar #PolarGO #GNMusic #AudioInterface #RecordingGear
September 15, 2026 at 10:48 PM
August 26, 2026 at 11:58 PM
Polargo fanart for @scarffles.bsky.social!

I wanted to do some brush tests so I used their Fakemon as a test subject
_____
[ #pokemon #fakemon ]
May 12, 2026 at 8:56 PM
A no. of trials in RR DLBCL with RGemOx as comparator all show:
• PFS med 2-3 mo
• OS med 12-13 mo
Well known tox of neutropenia, PN, fatigue, thrombocytopenia etc.

Beaten by exptl arms in StarGlo, Polargo, Sunmo

Take home: no more RGemOx pls - it’s defeated!
#18ICML #lymsm
June 18, 2025 at 9:13 PM
Sancho et al - POLARGO.
• RGemOx vs Pola-RGemOx R/R DLBCL
• 2L+ DLBCL (no ASCT eligible if 2L)
• OS primary EP: signif adv 12.5mo vs 19.5mo
• PFS & CMR rate better
• tox modest - ⬆️ infn & PN
• no effect of cell of origin
Interesting but ? value if 1L PolaRCHP
#18ICML
June 18, 2025 at 1:14 PM
📝 Results from the phase III POLARGO trial, presented by Matthew Matasar at #EHA2025, found that Pola-R-GemOx vs R-GemOx improved OS and PFS in transplant-ineligible patients with R/R DLBCL.

More news: LymphomaHub.com

#Lymphoma #lymsm #MedNews #MedEd
August 18, 2025 at 2:07 PM
New data 📝Results from the phase III POLARGO trial, presented by Matthew Matasar at #EHA2025, show that Pola-R-GemOx improved OS in transplant-ineligible patients with R/R DLBCL vs R-GemOx (p = 0.0017).

Learn more: https://loom.ly/14mTZQs

#Lymphoma #lymsm #MedNews #MedEd
August 14, 2025 at 2:08 PM
So strange how we don't have a proper Ice/Dragon type, huh?

So I have made: Berkub, Dracursa and Polargo! All Ice/Dragon type!

===
#fakemon #art #monsterdesign
November 9, 2025 at 8:38 PM
In the phase III POLARGO trial, @drmatasar.bsky.social reported that adding polatuzumab vedotin to R-GemOx reduced mortality by ~40% in relapsed/refractory DLBCL.
📊 270 patients
⏱️ Median OS: 19.5 vs 12.5 months (HR 0.60)
🔗 ascopost.com/issues/july-...
#DLBCL #PolatuzumabVedotin
July 29, 2025 at 7:48 PM
Polargo había oído yo decir que este juego era muy divertido...
January 1, 2025 at 8:07 PM
Adding polatuzumab vedotin to treatment with R-GemOx can improve survival outcomes in patients with R/R diffuse large B-cell #lymphoma. Presented at @hemasphere-journal.bsky.social #EHA2025.

bit.ly/4lLWJSn

#DLBCL #lymphsm
Polatuzumab Vedotin Improves PFS, OS in Rel/Ref DLBCL - Hematology Advisor
Results from the POLARGO trial “reinforce the benefit of adding polatuzumab to chemoimmunotherapy,” said Matthew Matasar, MD.
bit.ly
July 15, 2025 at 3:34 PM
OncoPharm
A Decade of CAR-T, Ocra-T, & POLARGO
OncoPharm · Episode
open.spotify.com
July 13, 2026 at 12:27 PM
OncoPharm
A Decade of CAR-T, Ocra-T, & POLARGO
OncoPharm · Episode
open.spotify.com
July 13, 2026 at 12:25 PM
Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial. ascopubs.org/doi/10.1200/...
Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial
PURPOSEPatients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) face an unfavorable prognosis once first-line treatment fails; therefore, there is an unmet need for new treatme...
ascopubs.org
July 10, 2026 at 9:36 AM